Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716965 | 0.82 | KMT2A (0.54) | MEN1KMT2ARAB9AALDH1A1TDP1 | |
| SCHEMBL6972381 | 0.81 | NQO2 (0.63) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| SCHEMBL10430138 | 0.78 | MEN1 (0.52) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7709064 | 0.77 | TLR8 (0.46) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| SCHEMBL5796954 | 0.77 | RAD52 (0.54) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| SCHEMBL9410439 | 0.76 | MEN1 (0.48) | MEN1KMT2ARAB9AALDH1A1TDP1 | |
| SCHEMBL9406598 | 0.76 | TLR8 (0.57) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| SCHEMBL31124812 | 0.76 | NQO2 (0.56) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| SCHEMBL18631848 | 0.76 | MEN1 (0.60) | MEN1KMT2ARAB9ANQO2ALDH1A1 | |
| SCHEMBL2918502 | 0.75 | NQO2 (0.45) | MEN1KMT2ANQO2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257538-B1 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-1261325-B1 | TUMOR INHIBITING COMPOSITIONS COMPRISING NITROACRIDINES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7622478-B2 | 1-nitroacridine/tumor inhibitor compositions | TIWARI RAJ | 2009-11-24 | — | — | US | disclosed |
| US-6589961-B2 | For inhibiting metastases of a tumor in a mammal | NEW YORK MEDICAL COLLEGE | 2003-07-08 | — | — | US | disclosed |
| EP-1261325-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NEW YORK MEDICAL COLLEGE | 2002-07-25 | — | — | US | disclosed |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | TIWARI RAJ (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2001060351-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | disclosed |
| US-5948906-A | CROWN ETHERS THAT CONTAIN AT LEAST ONE CORE NITROGEN THAT ARE LINKED VIA THE CORE NITROGEN(S) TO AT LEAST ONE FLUOROPHORE THAT CONTAINS AN ADDITIONAL HETEROAROMATIC LIGANDING THE CENTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0369733-B1 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | UNIV CALIFORNIA (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5134232-A | Diagnosis; concentration in blood | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NPPA, ABCB11, ABCC9 | MEN1 1499/4885KMT2A 3892/4885RAB9A 213/4885 |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | MKI67, DIAPH1, API5 | MEN1 369/4885KMT2A 2779/4885RAB9A 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.